New Coagulation Monitoring Device Allows for Wireless Reporting of INR Results

The system is intended for properly selected trained users ≥22 years of age who have been stabilized on anticoagulation with vitamin K antagonists for ≥6 weeks.

Roche is expected to launch the CoaguChek Vantus system, the first Bluetooth-enabled, self-testing device for coagulation monitoring, this summer.

The new system will allow patients to monitor International Normalized Ratio (INR) and send results wirelessly to healthcare providers via an app, the CoaguChek Link; other features include medication and testing reminders. 

“As healthcare systems face continued pressure to deliver improved access to care at a lower cost, increased connectivity between healthcare providers and patients becomes even more important,” said Dr. Alan Wright, CMO, Roche Diagnostics. According to a 2016 study (Heneghan CJ, 2016), self-testing of oral anticoagulation therapy resulted in fewer thromboembolic events when compared with lab testing.  

Related Articles

The system is intended for properly selected trained users ≥22 years of age who have been stabilized on anticoagulation with vitamin K antagonists for ≥6 weeks. 

For more information visit usinfo.roche.com.